Spotlight on Bladder Cancer Developments at 2024 AUA Annual Meeting

3D illustration of bladder cancer: © pikovit - stock.adobe.com

The 2024 American Urological Association (AUA) Annual Meeting took place May 2 to 6 in San Antonio, Texas, and data from across the field of urologic oncology were shared.

Many of the most anticipated findings came from studies in non-muscle-invasive bladder cancer (NMIBC). These included updated findings from the phase 2 SunRISe-1 study (NCT04640623) investigating TAR-200 in patients with Bacillus Calmette-Guérin (BCG)-unresponsive NMIBC. The phase 3 BOND-003 trial (NCT04452591) also found that cretostimogene grenadenorepvec delivered a high complete response (CR) rate in patients with high-risk NMIBC.

Additionally, findings from the phase 1 dose-escalating portion and interim phase 2 data of the LEGEND study (NCT04752722) showed that EG-70 (detalimogene voraplasmid) delivered a promising CR rate in this patient population.

Here are some of the highlights from the 2024 AUA Annual Meeting.

75.2% CR Rate: Cretostimogene Monotherapy Effective in High-Risk NMIBC

Sustained and durable CRs over 12 months were seen with cretostimogene grenadenorepvec, a novel investigational oncolytic immunotherapy, among patients with high-risk BCG-unresponsive NMIBC with carcinoma in situ (CIS), according to findings from the phase 3 BOND-003 trial.

EG-70 Elicits Promising Complete Responses in NMIBC

EG-70, a novel, nonviral gene therapy, elicited a 73% CR at any time for patients with NMIBC with CIS, according to findings from the phase 1 dose-escalating portion and interim phase 2 data of the LEGEND study.

Apalutamide/ADT Delivers 100% RFS at 2 Years in High-Risk Prostate Cancer

Treatment with apalutamide (Erleada) and androgen deprivation therapy (ADT) led to a biochemical recurrence-free survival rate of 100% (90% CI, 93.0-100.0) at 24 months among patients with high-risk localized prostate cancer who have undergone radical prostatectomy, according to findings from the phase 2 Apa-RP study (NCT04523207).

Durable Responses Seen with TAR-200 in BCG-Unresponsive NMIBC

TAR-200, the novel targeted gemcitabine delivery system, delivered rapid and durable responses in patients with BCG-unresponsive high-risk NMIBC, according to data from the phase 2 SunRISe-1 trial.

No Benefit in DFS or OS Seen With Extended Lymphadenectomy vs Standard in Urothelial Cancer

Patients who underwent extended lymph node dissection during radical cystectomy compared with those who underwent standard lymph node dissection exhibited no benefit in disease-free survival or overall survival, according to findings from a subgroup analysis of the phase 3 SWOG S1011 trial (NCT01224665).

Inclusion of PSMA-PET to mpMRI May Better Clinical Evaluation of Patients on Active Surveillance

Adding PSMA-PET imaging to multi-parametric MRI correlated with better detection of clinically significant prostate cancer in men who are being actively monitored, according to an interim analysis of a phase 2 study.

Key Findings From BOND-003: Cretostimogene Grenadenorepvec in NMIBC

In an interview with Targeted Oncology, Mark D. Tyson, II, MD, MPH, a urologic oncologist at Mayo Clinic in Phoenix, Arizona, discusses the safety and efficacy findings from the BOND-003 trial of cretostimogene grenadenorepvec for the treatment of patients with high-risk BCG-unresponsive NMIBC with CIS.

Williams on the Phase 3 SunRISe-2 Study of TAR-200/Cetrelimab in MIBC

In an interview with Targeted Oncology, Stephen Williams, MD, MBA, MS, FACS, FACHE, professor and chief of the Division of Urology, Department of Surgery at the University of Texas Medical Branch in Galveston, TX, discusses TAR-200 in muscle-invasive bladder cancer and the phase 3 SunRISe-2 study (NCT04658862) that was presented as part of the Clinical Trials in Progress program.